SCHEMBL27097601

SCHEMBL27097601

CC1CCN(CCO[C@H]2C[C@H](C)C2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.50
▸ CARM1 Q86X55 1/20 0.46
▸ PRMT6 Q96LA8 1/20 0.46
▸ PRMT1 Q99873 1/20 0.46
▸ PRMT8 Q9NR22 1/20 0.46
▸ SIGMAR1 Q99720 3/20 0.44
▸ KDM4E B2RXH2 4/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HRH3 Q9Y5N1 6/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ RECQL P46063 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27097577 0.85 NPC1 (0.55) NPC1CYP1A2CYP2D6HRH3TDP1
SCHEMBL27097472 0.85 NPC1 (0.55) NPC1CYP1A2CYP2D6HRH3TDP1
SCHEMBL25565671 0.83 NPC1 (0.53) NPC1CARM1PRMT6PRMT1PRMT8
SCHEMBL26949128 0.78 NPC1 (0.47) NPC1CARM1PRMT6PRMT1PRMT8
SCHEMBL14654909 0.77 NPC1 (0.60) NPC1CARM1PRMT6PRMT1PRMT8
SCHEMBL12607 0.75 ALDH1A1 (0.53) CARM1PRMT6PRMT1PRMT8SIGMAR1
SCHEMBL27271088 0.75 NPC1 (0.45) NPC1CARM1PRMT6PRMT1PRMT8
SCHEMBL27097434 0.74 HRH3 (0.43) NPC1KDM4ECYP2D6CYP2C19HRH3
SCHEMBL27097534 0.74 HRH3 (0.43) NPC1KDM4ECYP2D6CYP2C19HRH3
SCHEMBL14385014 0.74 CARM1 (0.50) CARM1PRMT6PRMT1PRMT8SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NPC1 2550/4885CARM1 385/4885PRMT6 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback